Legend Biotech Corporation (NASDAQ: LEGN), based in Bridgewater, New Jersey, disclosed long‑term results from its CARTITUDE‑2 Cohort A study at the 2026 International Myeloma Society Annual Meeting in Glasgow. The trial evaluated CARVYKTI, a BCMA‑directed autologous T‑cell therapy developed with Janssen Biotech, a Johnson & Johnson subsidiary.
The cohort comprised 20 patients with relapsed or refractory multiple myeloma who had received one to three prior therapy lines. After a single CARVYKTI infusion and without subsequent maintenance, 10 patients (50%) remained alive and progression‑free at a median follow‑up of 60.7 months, roughly double the prior 30‑month cut. The five‑year overall survival rate was 69.2%, and median progression‑free survival reached 60.5 months. Median overall survival had not been reached at the time of analysis.
Safety outcomes were consistent with the known profile of CARVYKTI. No new CAR‑T‑related neurotoxicity was observed. One patient developed acute myeloid leukemia, and two deaths were reported—one from disease progression and another from a new cancer.
Legend Biotech received U.S. FDA approval for CARVYKTI in February 2022 for adults with relapsed or refractory multiple myeloma and expanded the indication in April 2024 to include second‑line treatment after at least one prior therapy.
Multiple myeloma, a malignancy of plasma cells, is projected by the American Cancer Society to affect more than 36,000 Americans in 2026, underscoring the clinical relevance of durable therapies such as CARVYKTI.
